Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Verosudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 2/20 | 0.64 |
| ▸ | ROCK1 known ✓ | Q13464 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | F9 | P00740 | 4/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 11/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verosudil SCHEMBL31296114 | 1.00 | ROCK2 (0.64) | ROCK2ROCK1ALDH1A1F9GRM4 | |
| Verosudil SCHEMBL1095928 | 1.00 | ROCK2 (0.64) | ROCK2ROCK1ALDH1A1F9GRM4 | |
| Verosudil SCHEMBL1095927 | 1.00 | ROCK2 (0.64) | ROCK2ROCK1ALDH1A1F9GRM4 | |
| Verosudil SCHEMBL31296118 | 1.00 | ROCK2 (0.64) | ROCK2ROCK1ALDH1A1F9GRM4 | |
| Verosudil SCHEMBL29478425 | 1.00 | ROCK2 (0.64) | ROCK2ROCK1ALDH1A1F9GRM4 | |
| Verosudil SCHEMBL1097105 | 0.99 | ROCK2 (0.66) | ROCK2ROCK1ALDH1A1F9GRM4 | |
| Verosudil SCHEMBL30518358 | 0.99 | ROCK2 (0.66) | ROCK2ROCK1ALDH1A1F9GRM4 | |
| Verosudil SCHEMBL16036842 | 0.99 | ROCK2 (0.66) | ROCK2ROCK1ALDH1A1F9GRM4 | |
| Verosudil SCHEMBL30518344 | 0.99 | ROCK2 (0.66) | ROCK2ROCK1ALDH1A1F9GRM4 | |
| Verosudil SCHEMBL31296115 | 0.99 | ROCK2 (0.66) | ROCK2ROCK1ALDH1A1F9GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160243105-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2016-08-25 | — | — | US | claimed |
| US-20140275160-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2014-09-18 | — | — | US | claimed |
| EP-4335507-A2 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4218759-A2 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3811943-B1 | COMPOUND FOR USE IN THE TREATMENT OF OCULAR DISORDERS | AERIE PHARMACEUTICALS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-109528721-B | Combination therapy | 爱瑞制药公司 | 2021-10-01 | — | — | CN | disclosed |
| EP-3461484-B9 | DIMESYLATE SALTS OF 4-(3-AMINO-1-(ISOQUINOLIN-6-YLAMINO)-1-OXOPROPAN-2-YL)BENZYL, THEIR COMBINATIONS WITH PROSTAGLANDINS AND THE USE THEREOF IN THE TREATMENT OF OCULAR DISORDERS | AERIE PHARMACEUTICALS INC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3811943-A1 | COMPOUND FOR USE IN THE TREATMENT OF OCULAR DISORDERS | Aerie Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3461484-B1 | DIMESYLATE SALTS OF 4-(3-AMINO-1-(ISOQUINOLIN-6-YLAMINO)-1-OXOPROPAN-2-YL)BENZYL, THEIR COMBINATIONS WITH PROSTAGLANDINS AND THE USE THEREOF IN THE TREATMENT OF OCULAR DISORDERS | AERIE PHARMACEUTICALS INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200276179-A1 | Combination Therapy | ALCON INC. (CH) | 2020-09-03 | — | — | US | disclosed |
| US-10588901-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3461484-A1 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20180344724-A1 | Combination Therapy | ALCON INC. (CH) | 2018-12-06 | — | — | US | disclosed |
| US-9993470-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9849122-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170281613-A1 | Combination Therapy | ALCON INC. (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20160243105-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20140275160-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275160-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885ALDH1A1 1638/4885 |
| US-10588901-B2 | Combination therapy | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885ALDH1A1 1638/4885 |
| US-20160243105-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885ALDH1A1 1638/4885 |
| US-20170281613-A1 | Combination Therapy | PTGIR, PTGS1, PTGIS | ROCK2 430/4885ROCK1 582/4885ALDH1A1 886/4885 |
| US-20180344724-A1 | Combination Therapy | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885ALDH1A1 1638/4885 |
| US-20200276179-A1 | Combination Therapy | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885ALDH1A1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.